Immunovant Inc

Insider sell‑to‑cover by Immunovant COO shows routine tax coverage, not a strategic divest. Her steady long‑term stake still backs the company’s promising arthritis pipeline.

Insider buying at Immunovant signals long‑term confidence amid a steep price climb—yet negative earnings and future capital needs caution investors.

Insider buying spurs confidence in Immunovant, with executives buying over 140,000 shares amid market volatility, while tax‑cover sales show routine RSU management.

CEO Eric Venker’s April 2026 share buy‑back, after vesting CVARs, signals strong confidence in Immunovant’s recovery and future milestones.

Immunovant insider sell‑to‑cover by COO Gloria Melanie shows routine tax compliance amid broader executive trading; investors watch for future discretionary sales and potential market impact.